Yf Yu

AD2: MEDICATION TREATMENT PERSISTENCE OF OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS IN A CALIFORNIA MEDICAID PROGRAM AND THE BENEFIT OF THEIR REFILL ADHERENCE ON URINARY TRACK INFECTION

costs. In this model, prescription non-procurement was more likely to be reported in the Medicare-only population (OR: 1.47; 95% CI 1.46–1.48) and in the Medicare plus Medicaid population (OR: 1.11; 95% CI 1.10–1.12) as compared to respondents with Medicare plus private insurance coverage. CONCLUSIONS: Significantly different rates of persons who forego filling a prescription for cost reasons were observed among Medicare beneficiaries. More vulnerable groups of seniors were identified. Dual eligible Medicare/Medicaid enrollees and those with Medicare alone are more likely to restrict medication procurement due to cost.

PRK5: ANALYSIS OF COMORBIDITY, HOSPITAL UTILIZATION AND COST OF OVERACTIVE BLADDER IN A CALIFORNIA MEDICAID PROGRAM—A CASE-CONTROL STUDY

OBJECTIVES: To explore the possible comorbidities associated with Overactive Bladder (OAB), and to estimate the resource utilization pattern and cost of OAB in a Medicaid population. METHODS: A retrospective case-control matching study was performed. Five thousand five hundred seven continuously enrolled Medi-Cal patients who were diagnosed with OAB and received OAB prescriptions from 1999 to 2001 were 1 :2 matched based on age, gender, race, and residence county. Annual hospital utilization and cost were calculated for both OAB and matched control cohorts, and prevalence ratios (PR, OAB over control) for 34 ICD-9 based comorbidity measures from AHRQ were examined. RESULTS: Out of 34 comorbidities, 13 occurred in OAB patients at least twice as much as in general Medicaid population: paralysis (PR = 10.46), urinary track infection (UTI, PR = 3.74), other neurological (PR = 2.79), peripheral vascular disorder (PR = 2.42), valvular disease (PR = 2.32), arrhythmias (PR = 2.31), atopic dermatitis (PR = 2.19), blood loss anemia (PR = 2.14), depression (PR = 2.10), pulmonary circulation disorder (PR = 2.10), hypothyroidism (PR = 2.08), peptic ulcer disease including bleeding (PR = 2.08), and deficiency anemias (PR = 2.05). Among these diagnoses, obesity, UTI, dermatitis and depression are known comorbidities related to OAB. OAB patients had much higher annual resource utilization than the matched control group: physician office encounters (27.39 vs. 2.70, P < 0.0001), and an emergency room visits (0.26 vs. 0.04, P < 0.0001). OAB patients had approximately two-fold higher costs than the control cohort for pharmacy and medical services:

Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in the California Medicaid Program

3319.85 vs.

Delay in Filling the Initial Prescription for a Statin: A Potential Early Indicator of Medication Nonpersistence

1560.06 (P < 0.0001),

PMC33 BRIDGING BEYOND REGRESSION-ARTIFICIAL NEURAL NETWORK IN MAPPING FROM SF-36 TO HEALTH UTILITY

4754.86 vs.

PRK1: COMPARISON OF DIRECT HEALTH-CARE COST, HOSPITAL UTILIZATION AND MEDICATION PERSISTENCE BETWEEN EXTENDED RELEASE FORMS (ER) OF TOLTERODINE AND OXYBUTYNIN IN OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS

2592.68 (P < 0.0001). CONCLUSIONS: OAB patients who received drug treatment incurred a heavy economic and resource burden to the California Medicaid program. Comorbid conditions were much more prevalent in the OAB cohort than in the general Medicaid population.